Evidence map›Paper›PMID 27062566›Full record

ArticleCancer biomarkers : section A of Disease markers2016

KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.

Karen Bento Ribeiro, Juliana da Silva Zanetti, Alfredo Ribeiro-Silva, Liane Rapatoni, Harley Francisco de Oliveira, Daniela Pretti da Cunha Tirapelli, Sergio Britto Garcia, Omar Feres, José Joaquim Ribeiro da Rocha, Fernanda Maris Peria

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Association ofInternational journal of molecular sciences · 2024
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Inhibition of colon cancer K-RasFrontiers in pharmacology · 2022
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. The Prognostic Value ofMolecular imaging and radionuclide therapy · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. HotspotOncotarget · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Karen Bento RibeiroInternal Medicine Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Juliana da Silva ZanettiPathology and Legal Medicine Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Alfredo Ribeiro-SilvaPathology and Legal Medicine Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Liane RapatoniInternal Medicine Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Harley Francisco de OliveiraInternal Medicine Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Daniela Pretti da Cunha TirapelliSurgery and Anatomy Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Sergio Britto GarciaSurgery and Anatomy Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Omar FeresSurgery and Anatomy Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
José Joaquim Ribeiro da RochaSurgery and Anatomy Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Fernanda Maris PeriaInternal Medicine Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMultiple stages of carcinogenesis in colon cancer encompass subpopulations of cancer stem cells (CSC), responsible for tumor cell transformation, growth and proliferation. CD44 and CD166 proteins are CSC markers associated with cell signaling, adhesion, migration, metastasis and lymphocytic response. The expression of CSC may be modulated by some factors, such as the KRAS gene mutation.

objectiveCorrelate the expression of CD44 and CD166 markers in metastatic colon adenocarcinoma and KRAS mutation status (wild-type/mutated) with clinical pathological features and patients' outcome. MATERIAL AND

methodsFifty-eight samples of tumor tissue samples of metastatic colon adenocarcinoma were collected from patients treated with CapeOx at the HCFMRP-USP Clinical Oncology Service. Clinical and survival data were collected from medical records. KRAS status was determined by the polymerase chain reaction (PCR) technique, and analysis of immunohistochemical expression of CD44 and CD166 proteins was performed by tissue microarray.

resultsThe expression of CD44 and CD166 were positive in 41% and 43% of patients, respectively, and mutated KRAS was detected in 48% of patients. A significant association was found between CD166 and CD44 expression (p= 0.016), mainly in the wild-type KRAS group (p= 0.042) and patients over 65 years (p= 0.001). CD44-positive patients had 3.7-fold and 5.3-fold greater risk of liver metastasis and lung metastasis, respectively (p< 0.01), compared with CD44-negative patients. CD166-negative patients had 2.7 greater risk of lymph node involvement (0.03), compared with CD166-positive patients. KRAS mutation increased the risk of liver metastasis by 8 times (p< 0.01), and the risk of lung metastasis by 5 times (p= 0.04) in CD44-positive patients. KRAS mutation increased the risk of lymph node involvement by 8 times in CD166-negative patients (p= 0.0007).

conclusionAn association between CD44 and CD166 expression was demonstrated in this study. Analysis of KRAS mutation combined with immunohistochemical expression of CD44 and CD166 identified subgroups of patients with colon adenocarcinoma at higher risk of lymph node involvement by the tumor and development of liver and lung metastasis.

Indexed as

MutationActivated-Leukocyte Cell Adhesion MoleculeAgedAged, 80 and overBiomarkers, TumorColonic NeoplasmsFemaleHumansHyaluronan ReceptorsImmunohistochemistryMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingNeoplastic Stem CellsActivated-Leukocyte Cell Adhesion MoleculeBiomarkers, TumorHyaluronan Receptorsras Proteinsbiomarkercancer stem cellColon cancerKRAS mutation

Identifiers

PMID27062566
PMCPMC13016524
OpenAlexW2340014362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.